| Reference | Treatment | Number of patients | OS median (months) |
| Milella et al. 200437 | 5-FU + celecoxib | 17 | 3.5 |
| Cantore et al. 200438 | Irinotecan + oxaliplatin | 30 | 5.9 |
| Androulakis et al. 200539 | Oxaliplatin | 18 | 3.5 |
| Demols et al. 200640 | Gemcitabine + oxaliplatin | 33 | 6.0 |
| Ignatiadis et al. 200641 | Docetaxel + gefitinib | 26 | 2.9 |
| Boeck et al. 200742 | Pemetrexed | 52 | 4.6 |
| Kulke et al. 200716 | Capecitabine + erlotinib | 30 | 6.5 |
| Xiong et al. 200818 | Oxaliplatin + capecitabine | 39 | 5.7 |
| Wolpin et al. 200943 | Everolimus | 33 | 4.5 |
| Pelzer et al. 201130 | Oxaliplatin, folinic acid + 5-FU | 23 | 4.8 |
| Pelzer et al. 201130 | BSC | 23 | 2.3 |
| Burzynski et al. 2014 | PB + a targeted combination | 14 | 10.5 |